Massive Bio Drug Matching Software

Massive Bio has announced plans to introduce an artificial intelligence-powered drug matching software product in the first half of 2023. The unnamed product, which will be targeted toward oncologists, biotech, and pharmaceutical companies, will build on the the company's Synergy-AI global registry for clinical trial matching, which now counts more than 100,000 enrollees. It will also complement the 100K Cancer Clinical Trial Singularity Program, Massive Bio's ambitious plan to apply AI to improve clinical trial matching for cancer patients.